financial news: Immunovaccine Nominates Brad Thompson for Appointment to the Board - DepoVax™

Brad Thompson, Ph.D., is Executive Chairman, Chief Executive Officer and President of Oncolytics Biotech Inc. and is the current Chairman of BIOTECanada. Prior to joining Oncolytics, he served as Chief Executive Officer of Iteration Energy Ltd. (formerly SYNSORB Biotech Incorporated), from May 1994 to February 1999, and was Head of Biotechnology at The Alberta Research Council. Dr. Thompson received his Ph.D. from the University of Western Ontario in the Department of Microbiology and Immunology.

Immunovaccine Inc. (TSX VENTURE:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented vaccine delivery technology and product candidates.